1,306 results on '"Ocular melanoma"'
Search Results
2. Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
- Author
-
Merck Sharp & Dohme LLC, National Institutes of Health (NIH), National Cancer Institute (NCI), and Mohammad K. Khan, Principal Investigator
- Published
- 2024
3. A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)
- Published
- 2024
4. Neoadjuvant and Adjuvant Checkpoint Blockade
- Author
-
National Cancer Institute (NCI)
- Published
- 2024
5. Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Author
-
Merck Sharp & Dohme LLC
- Published
- 2024
6. Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
- Author
-
Turnstone Biologics, Corp.
- Published
- 2024
7. Study in Subjects With Small Primary Choroidal Melanoma
- Published
- 2024
8. Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma (NADOM)
- Author
-
St Vincent's Hospital, Sydney and Anthony Joshua, FRACP, Head of Medical Oncology
- Published
- 2024
9. Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
- Published
- 2023
10. Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma (PROTECT)
- Published
- 2023
11. Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) (Mel66)
- Author
-
Celldex Therapeutics and Craig L Slingluff, Jr, Professor of Surgery; Director, Human Immune Therapy Center
- Published
- 2023
12. Multiple neoplasms in patients with uveal melanoma: a systematic review.
- Author
-
de Esteban Maciñeira, Elia, Fernández Fernández, Pablo, Conde González, Iria, Bande Rodríguez, Manuel Francisco, and Blanco Teijeiro, María José
- Abstract
Purpose: Uveal melanoma is the most prevalent intraocular malignancy in adults, derived from uveal tract melanocytes. This study focuses on the frequency and risk of second primary malignancies in UM patients. Methods: A PubMed search (1980–2023) identified studies on SPM incidence in UM patients. From 191 references, 14 studies were chosen, focusing on UM, SPMs, and analysing data on demographics and types of neoplasms. Results: Among 31,235 UM patients in 14 studies, 4695 had 4730 SPMs (15.03% prevalence). Prostate (15%), breast (12%), and colorectal (9%) cancers were most common. Digestive system malignancies were highest (19%), with colorectal cancer leading (51%). Breast and prostate cancers were prevalent in respective systems. Lung, bladder, and non-Hodgkin's lymphoma were also notable. The study observed an increasing trend in the frequency of SPMs over time, reflecting broader trends in cancer survivorship and the growing prevalence of multiple malignancies. Conclusion: The study highlights a significant presence of SPMs in UM patients, with an increasing trend in frequency over time, emphasizing prostate and breast cancers. This underscores the need for focused surveillance and tailored follow-up for UM survivors, considering their higher risk of additional malignancies. Future research should further investigate SPM aetiology in UM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Femtosecond pulsed laser photodynamic therapy activates melanin and eradicates malignant melanoma.
- Author
-
Pires, Layla, Khattak, Shireen, Pratavieira, Sebastiao, Calcada, Carla, Romano, Renan, Yeni Yucel, Bagnato, Vanderlei S., Kurachi, Cristina, and Wilson, Brian C.
- Subjects
- *
PHOTODYNAMIC therapy , *FEMTOSECOND lasers , *LASER therapy , *MELANINS , *MELANOMA - Abstract
Photodynamic therapy (PDT) relies on a series of photophysical and photochemical reactions leading to cell death. While effective for various cancers, PDT has been less successful in treating pigmented melanoma due to high light absorption by melanin. Here, this limitation is addressed by 2-photon excitation of the photosensitizer (2p-PDT) using ~100 fs pulses of near-infrared laser light. A critical role of melanin in enabling rather than hindering 2p-PDT is elucidated using pigmented and non-pigmented murine melanoma clonal cell lines in vitro. The photocytotoxicities were compared between a clinical photosensitizer (Visudyne) and a porphyrin dimer (Oxdime) with ~600-fold higher σ2p value. Unexpectedly, while the 1p-PDT responses are similar in both cell lines, 2p activation is much more effective in killing pigmented than non-pigmented cells, suggesting a dominant role of melanin 2p-PDT. The potential for clinical translational is demonstrated in a conjunctival melanoma model in vivo, where complete eradication of small tumors was achieved. This work elucidates the melanin contribution in multi-photon PDT enabling significant advancement of light-based treatments that have previously been considered unsuitable in pigmented tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma
- Author
-
Bristol-Myers Squibb and Suthee Rapisuwon, Sponsor-Investigator
- Published
- 2023
15. Unveiling the importance role of lutein-plant-based nanoencapsulation – a future effort to improve their stability and bioaccessibility in combating ocular melanoma
- Author
-
Happy Kurnia Permatasari, Fahrul Nurkolis, Muhammad Iqhrammullah, Rony Abdi Syahputra, Rudy Kurniawan, Dionysius Subali, Reggie Surya, Dian Aruni Kumalawati, Faqrizal Ria Qhabibi, Vika Anggari, Raymond R. Tjandrawinata, Nelly Mayulu, Hardinsyah Hardinsyah, Nurpudji Astuti Taslim, Andi Yasmin Syauki, and Bonglee Kim
- Subjects
Lutein ,molecular oncology ,natural product ,nanoencapsulation technology ,ocular melanoma ,carotenoids ,Nutrition. Foods and food supply ,TX341-641 ,Food processing and manufacture ,TP368-456 - Abstract
ABSTRACTDespite its potential benefits, lutein availability can be limited due to inadequate dietary intake of fruits, vegetables, and seaweed. Additionally, lutein faces challenges related to gastrointestinal absorption due to its physicochemical characteristics. To tackle these issues, fortifying staple foods with lutein is proposed, but its low solubility and susceptibility to oxidative degradation present hurdles. Nanoencapsulation technology emerges as a promising solution for improving lutein stability during food processing, storage, and absorption. However, lutein’s stability remains a challenge, with susceptibility to degradation by temperature, UV-light, and oxygen exposure. Food processing involving high temperatures can cause degradation, while specific UV-wavelengths lead to cleavage of lutein molecules. This critical viewpoint carries substantial scientific significance by urging researchers globally to prioritize clinical investigations and the advancement of plant-based lutein nanoencapsulation in basic dietary items. Clinical studies focusing on lutein-plant-based nanoencapsulation approaches are essential to improve its stability and bioaccessibility, ultimately contributing to better vision health.
- Published
- 2024
- Full Text
- View/download PDF
16. Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline.
- Author
-
Weis, Ezekiel, Surgeoner, Brae, Salopek, Thomas G., Cheng, Tina, Hyrcza, Martin, Kostaras, Xanthoula, Larocque, Matthew, McKinnon, Greg, McWhae, John, Menon, Geetha, Monzon, Jose, Murtha, Albert D., Walker, John, and Temple-Oberle, Claire
- Subjects
- *
UVEA cancer , *VASCULAR endothelial growth factor antagonists , *CANCER treatment , *MEDICAL personnel - Abstract
Objective: The purpose of this guideline update is to reassess and update recommendations in the prior guideline from 2016 on the appropriate management of patients with uveal melanoma. Methods: In 2021, a multidisciplinary working group from the Provincial Cutaneous Tumour Team, Cancer Care Alberta, Alberta Health Services was convened to update the guideline. A comprehensive review of new research evidence in PubMed as well as new clinical practice guidelines from prominent oncology groups informed the update. An enhancement in methodology included adding levels of evidence and strength of recommendations. The updated guideline was circulated to all members of the Provincial Cutaneous Tumour Team for review and endorsement. Results: New and modified recommendations address provider training requirements, diagnostic imaging for the detection of metastases, neo-adjuvant pre-enucleation radiotherapy, intravitreal anti-vascular endothelial growth factor agents for radiation retinopathy, genetic prognostic testing, surveillance following definitive local therapy, and systemic therapy for patients with metastatic uveal melanoma. Discussion: The recommendations represent evidence-based standards of care agreed to by a large multidisciplinary group of healthcare professionals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. FBXO38 regulates ocular melanoma proliferation through the PI3K-Akt signaling pathway
- Author
-
WU Yijia, FANG Yan, SHEN Feiyang, HUANG Rui, SHEN Jianfeng, and FAN Xianqun
- Subjects
f-box only protein 38 (fbxo38) ,ocular melanoma ,pi3k-akt signaling pathway ,tumor proliferation ,Medicine - Abstract
Objective·To investigate the effect of F-box only protein 38 (FBXO38) on the ocular melanoma proliferation and the potential regulatory pathway.Methods·Human skin cutaneous melanoma A375 and human uveal melanoma OMM2.3 cell lines with FBXO38 knockdown and overexpression were constructed by FBXO38 short hairpin RNA (shRNA) and FBXO38 overexpression plasmids respectively. Knockdown and overexpression efficiency of FBXO38 at transcription and protein levels were verified by using quantitative real-time PCR (qRT-PCR) and Western blotting. The effects of FBXO38 on melanoma cell proliferation were detected through clonal formation assay, BrdU immunofluorescence staining and CCK8 cell proliferation assay. By using The Cancer Genome Atlas (TCGA) database, differentially expressed genes were analyzed in the high and low expression groups of FBXO38. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was performed to reveal the signaling pathways associated with FBXO38. CCK8 cell proliferation assay was used to detect the inhibition rates of the signaling pathway inhibitors on cells with different FBXO38 expression levels. qRT-PCR and Western blotting were used to detect whether the signaling pathway was activated after knocking down FBXO38.Results·qRT-PCR and Western blotting verified that mRNA and protein expression levels of FBXO38 in FBXO38 knockdown A375 and OMM2.3 cell lines decreased compared with the control group, while the expression levels of FBXO38 in the overexpression cell lines increased compared with wild type group (P
- Published
- 2023
- Full Text
- View/download PDF
18. Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline
- Author
-
Ezekiel Weis, Brae Surgeoner, Thomas G. Salopek, Tina Cheng, Martin Hyrcza, Xanthoula Kostaras, Matthew Larocque, Greg McKinnon, John McWhae, Geetha Menon, Jose Monzon, Albert D. Murtha, John Walker, and Claire Temple-Oberle
- Subjects
uveal melanoma ,ocular melanoma ,choroidal melanoma ,iris melanoma ,melanoma ,ophthalmology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objective: The purpose of this guideline update is to reassess and update recommendations in the prior guideline from 2016 on the appropriate management of patients with uveal melanoma. Methods: In 2021, a multidisciplinary working group from the Provincial Cutaneous Tumour Team, Cancer Care Alberta, Alberta Health Services was convened to update the guideline. A comprehensive review of new research evidence in PubMed as well as new clinical practice guidelines from prominent oncology groups informed the update. An enhancement in methodology included adding levels of evidence and strength of recommendations. The updated guideline was circulated to all members of the Provincial Cutaneous Tumour Team for review and endorsement. Results: New and modified recommendations address provider training requirements, diagnostic imaging for the detection of metastases, neo-adjuvant pre-enucleation radiotherapy, intravitreal anti-vascular endothelial growth factor agents for radiation retinopathy, genetic prognostic testing, surveillance following definitive local therapy, and systemic therapy for patients with metastatic uveal melanoma. Discussion: The recommendations represent evidence-based standards of care agreed to by a large multidisciplinary group of healthcare professionals.
- Published
- 2023
- Full Text
- View/download PDF
19. Bilateral axillary pigmented lesions in a melanoma patient
- Author
-
Shannon Gurley, BS and Jason Waldinger, MD
- Subjects
BAP1 gene ,melanoma ,metastatic melanoma ,ocular melanoma ,pigmented lesions ,uveal melanoma ,Dermatology ,RL1-803 - Published
- 2023
- Full Text
- View/download PDF
20. FBXO38 通过PI3K-Akt 信号通路调控眼部黑色素瘤增殖.
- Author
-
吴以加, 房燕, 沈菲洋, 黄蕊, 沈键锋, and 范先群
- Abstract
Objective·To investigate the effect of F-box only protein 38 (FBXO38) on the ocular melanoma proliferation and the potential regulatory pathway. Methods·Human skin cutaneous melanoma A375 and human uveal melanoma OMM2.3 cell lines with FBXO38 knockdown and overexpression were constructed by FBXO38 short hairpin RNA (shRNA) and FBXO38 overexpression plasmids respectively. Knockdown and overexpression efficiency of FBXO38 at transcription and protein levels were verified by using quantitative real-time PCR (qRT-PCR) and Western blotting. The effects of FBXO38 on melanoma cell proliferation were detected through clonal formation assay, BrdU immunofluorescence staining and CCK8 cell proliferation assay. By using The Cancer Genome Atlas (TCGA) database, differentially expressed genes were analyzed in the high and low expression groups of FBXO38. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was performed to reveal the signaling pathways associated with FBXO38. CCK8 cell proliferation assay was used to detect the inhibition rates of the signaling pathway inhibitors on cells with different FBXO38 expression levels. qRT-PCR and Western blotting were used to detect whether the signaling pathway was activated after knocking down FBXO38. Results·qRT-PCR and Western blotting verified that mRNA and protein expression levels of FBXO38 in FBXO38 knockdown A375 and OMM2.3 cell lines decreased compared with the control group, while the expression levels of FBXO38 in the overexpression cell lines increased compared with wild type group (P< 0.05). Clonal formation assay, BrdU immunofluorescence staining and CCK8 cell proliferation assay showed that FBXO38 knockdown significantly enhanced the proliferation of A375 and OMM2.3 cells (P<0.05), while overexpression of FBXO38 inhibited melanoma cell proliferation (P<0.05). Enrichment analysis showed that in skin cutaneous melanoma and uveal melanoma, FBXO38 expression influenced the phosphoinositide 3-kinase/protein kinase B (PI3K-Akt) pathway activation. Compared with those in the control group, the inhibition rates of PI3K inhibitor LY294002 and mTOR1 inhibitor Everolimus in the FBXO38 knockdown group significantly improved (P<0.05), while their inhibition rates of the overexpression group significantly decreased compared with those of control cells (P<0.05). Western blotting results showed that after knocking down FBXO38, expression levels of PTEN, P21 and P53 proteins decreased, while expression level of MDM2 protein increased. The qRT-PCR results showed a significant decrease in P53 transcription level (P<0.05) and a significant increase in MDM2 transcription level in FBXO38 knockdown cells (P<0.05). Conclusion·FBXO38 plays a role in regulating the proliferation of ocular melanoma, and this regulatory effect is related to the PI3K-Akt signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Unusual Presentation of Unilateral Choroidal Melanoma with Bilateral Vasculitis in Young Individual: A Case Report and Review of Literature
- Author
-
Saleh S Algamdi and Dhoha M Alhamad
- Subjects
melanoma ,vasculitis ,uveal melanoma ,choroidal melanoma ,macular lesion ,uveitis ,ocular melanoma ,masquerade. ,Internal medicine ,RC31-1245 - Abstract
Ocular melanoma stands as the predominant primary intraocular malignancy, albeit infrequently exhibiting ipsilateral inflammatory manifestations. In this article, we present an exceptional case involving a middle-aged male who presented with unilateral ocular choroidal melanoma alongside bilateral retinal vasculitis. The patient initially received temporary steroid treatment, followed by brachytherapy, which contributed to the resolution of vasculitis symptoms. The study aims to document the atypical occurrence of bilateral retinal vasculitis, which could potentially masquerade as melanoma, emphasizing the need for heightened vigilance and further investigations when encountering choroidal masses in its presence. Future research endeavors are warranted to better understand the incidence of such occurrences in this context.
- Published
- 2024
22. Promoting Adjustment in Uveal Melanoma Survivorship: A Randomized Trial Targeting Illness Perceptions
- Author
-
Hoch, Megan Michelle
- Subjects
Clinical psychology ,Chronic Illness ,Experimental Medicine ,Health Psychology ,Ocular Melanoma ,Psychoeducation ,Uveal Melanoma - Abstract
Introduction: This dissertation project was a randomized controlled trial of a brief psychoeducational intervention targeting three illness perceptions (chronicity, control, coherence) in a sample of uveal melanoma (UM) survivors at UCLA (N = 101). Illness perceptions have been shown to be associated with psychological and disease-related adjustment in the context of chronic illnesses at large (e.g., Hagger et al., 2017), and within UM patient populations specifically (e.g., Hoch et al., 2023). More positive (i.e., less threatening) illness perceptions have been shown to be associated with better mental health outcomes in the context of chronic illness. Method: The intervention consisted of two psychoeducational videos in which participants’ ocular oncologist discussed considerations for promoting mental, physical, and visual adjustment across the course of UM survivorship. The control group received an enhanced treatment as usual manipulation comprised of a mental health resource information sheet. Participants completed four study visits via online surveys, including a baseline visit (T0) during which they completed assessments and were randomized to the intervention (n = 53) or control (n = 48) condition and received their respective study manipulations. Assessments were repeated one (T1) and two (T2) weeks later, with a final assessment (T3) administered four weeks after the third study visit. I hypothesized that participants randomized to the treatment condition would evidence less threatening illness perceptions over the course of the study than would participants in the control condition. Results: Multilevel models tested interactions between study condition and time to evaluate treatment effects on illness perception and psychological distress outcomes. Number of years since UM diagnosis and pre-randomization levels of approach- and avoidance-oriented coping were included in separate models as moderators. No interactions between study condition and time were statistically significant (with or without additional moderator variables). Participants’ feedback suggested that both the psychoeducational and control interventions were rated as informative, acceptable, and credible. Participants reported that both interventions would have been particularly helpful at the time of UM diagnosis. Conclusion: We recommend that future trials test the psychoeducational intervention at more specific and relevant clinical milestones to optimize desired changes in illness perceptions (e.g., following UM diagnosis).
- Published
- 2024
23. Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi‐institutional study
- Author
-
Xin Liu, Han Yue, Shiyu Jiang, Lin Kong, Yu Xu, Yong Chen, Chunmeng Wang, Yan Wang, Xiaoli Zhu, Yunyi Kong, Xiaowei Zhang, Jiang Qian, and Zhiguo Luo
- Subjects
conjunctiva melanoma ,lacrimal sac melanoma ,ocular melanoma ,orbital melanoma ,uveal melanoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose Metastatic ocular and orbital melanomas are extremely rare. The clinical characteristics and standard treatments for these patients are not fully established. Materials and Methods We retrospectively analyzed patients with metastatic ocular and orbital melanoma from Fudan University Shanghai Cancer Center and Eye & ENT Hospital of Fudan University between January 2012 and May 2022. Results Overall, 51 patients with metastatic ocular and orbital melanoma were included. The most common primary sites were uvea (73%), followed by conjunctiva (22%), lacrimal sac (4%), and orbit (2%). Patients with uveal melanoma (UM) had a significantly younger age (48 vs. 68 years, p
- Published
- 2023
- Full Text
- View/download PDF
24. Ophthalmic applicator displacement as a method of treating large diffuse uveal melanomas
- Author
-
Anna Markiewicz, Konrad Skórkiewicz, Agata Bogdał, Dominik Medoń, Mirella Świder, Elżbieta Korab-Chrzanowska, Joanna Kowal, Magdalena Dębicka-Kumela, and Bożena Romanowska-Dixon
- Subjects
uveal melanoma ,applicator displacement ,plaque displacement ,brachytherapy ,enucleation ,ocular melanoma ,diffuse uveal melanoma ,ophthalmic applicator ,Medicine - Published
- 2023
- Full Text
- View/download PDF
25. Definity for Ultrasound of Intraocular Tumors
- Author
-
Hans Grossniklaus, MD, Professor
- Published
- 2022
26. Clinical features and prognosis of patients with metastatic ocular and orbital melanoma: A bi‐institutional study.
- Author
-
Liu, Xin, Yue, Han, Jiang, Shiyu, Kong, Lin, Xu, Yu, Chen, Yong, Wang, Chunmeng, Wang, Yan, Zhu, Xiaoli, Kong, Yunyi, Zhang, Xiaowei, Qian, Jiang, and Luo, Zhiguo
- Subjects
- *
MELANOMA , *LYMPHATIC metastasis , *EYE cancer , *METASTASIS , *PROGRESSION-free survival , *UNIVERSITY hospitals - Abstract
Purpose: Metastatic ocular and orbital melanomas are extremely rare. The clinical characteristics and standard treatments for these patients are not fully established. Materials and Methods: We retrospectively analyzed patients with metastatic ocular and orbital melanoma from Fudan University Shanghai Cancer Center and Eye & ENT Hospital of Fudan University between January 2012 and May 2022. Results: Overall, 51 patients with metastatic ocular and orbital melanoma were included. The most common primary sites were uvea (73%), followed by conjunctiva (22%), lacrimal sac (4%), and orbit (2%). Patients with uveal melanoma (UM) had a significantly younger age (48 vs. 68 years, p < 0.001), higher incidence of liver metastases (89% vs. 9%, p<0.001), a lower incidence of lymph nodes metastases (16% vs. 46%, p = 0.043) and a lower incidence of BRAF mutation (0% vs. 55%, p<0.001) compared with patients with conjunctival melanoma (CM). The overall response rate of the first‐line treatment was 18%. Three of the four patients with BRAF‐mutated CM responded to dabrafenib and trametinib treatment. The median progression‐free survival (PFS) and overall survival (OS) of first‐line treatment were 5.1 and 11.9 months, respectively. Among patients with liver metastases, liver‐directed treatment was correlated with better patient PFS (p < 0.001) and OS (p < 0.001) after adjusting for number of metastatic sites and primary sites. Conclusion: CM and UM have different characteristics. Patient with CM had a high incidence of BRAF mutation, and the treatment of BRAF and MEK inhibitors conferred clinical benefit. Liver directed therapies had a potential benefit in disease control in patients with liver metastases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Occupational Exposure to Solar Radiation and the Eye: A Call to Implement Health Surveillance of Outdoor Workers.
- Author
-
MODENESE, ALBERTO, CHOU, B. RALPH, ÁDÁM, BALÁZS, LONEY, TOM, PAULO, MARILIA SILVA, TENKATE, THOMAS, and GOBBA, FABRIZIOMARIA
- Abstract
Globally, hundreds of millions of outdoor workers are exposed to solar radiation (SR) for most of their work. Such occupational exposure is known to induce various adverse health effects on the eyes, mainly related to its ultraviolet (UV) component. The present work is a call to action to raise awareness of the need for health surveillance to prevent chronic ocular diseases in outdoor workers. Photo-chemical chronic damage can induce pterygium at the eye's outer layer and cataracts in the lens. Considering carcinogenic effects, rare squamous-cell tumors of the cornea and/or the conjunctiva and ocular melanomas are associated with UV radiation exposure. Solar UV-related eye diseases should be considered "occupational diseases" when workers have sufficient exposure. Still, they are often not recognized and/or frequently not reported to the national compensation authorities. Therefore, to prevent the burden of these workrelated eye pathologies, an adequate risk assessment with identification of appropriate preventive measures and a provision of periodic health surveillance to the exposed workers, particularly those at higher risk of exposure or with individual susceptibility, should be urgently implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
- Published
- 2021
29. Male sex as an independent predictor of poor disease‐specific survival in conjunctival melanoma.
- Author
-
Ituarte, Bianca E., Pitchyaiah, Prathishtha, Taylor, Mitchell A., Thomas, Sierra, Sharma, Divya, and Voss, Vanessa B.
- Published
- 2024
- Full Text
- View/download PDF
30. Immunotherapy for ocular melanoma: a bibliometric and visualization analysis from 1991 to 2022.
- Author
-
Yao Tan, Yijie Lu, Sheng Chen, Chang Zou, and Bo Qin
- Subjects
UVEA cancer ,BIBLIOMETRICS ,IMMUNE checkpoint inhibitors ,MELANOMA ,IMMUNOTHERAPY ,IMMUNOSUPPRESSION - Abstract
Background: In recent years, new therapeutic options to overcome the mechanisms of tumor immune suppression be effective in the treatment of cutaneous melanoma. These approaches have also been applied in ocular melanoma. The aim of this study is to present the current status and research hotspots of immunotherapy for ocular melanoma from a bibliometric perspective and to explore the field of immunotherapy for malignant ocular melanoma research. Methods: In this study, the Web of Science Core Collection database (WoSCC) and Pubmed were selected to search the literature related to immunotherapy of ocular melanoma. Using VOSviewer, CiteSpace, the R package "bibliometrix," and the bibliometric online platform through the construction and visualization of bibliometric networks, the country/region, institution, journal, author, and keywords were analyzed to predict the most recent trends in research pertaining to ocular melanoma and immunotherapy. Results: A total of 401 papers and 144 reviews related to immunotherapy of ocular melanoma were included. The United States is the main driver of research in the field, ranking first in terms of the number of publications, total citations, and H-index. The UNIVERSITY OF TEXAS SYSTEM is the most active institution, contributing the most papers. Jager, Martine is the most prolific author, and Carvajal, Richard is the most frequently cited author. CANCERS is the most published journal in the field and J CLIN ONCOL is the most cited journal. In addition to ocular melanoma and immunotherapy, the most popular keywords were "uveal melanoma" and "targeted therapy". According to keyword co-occurrence and burst analysis, uveal melanoma, immunotherapy, melanoma, metastases, bap1, tebentafusp, bioinformatics, conjunctival melanoma, immune checkpoint inhibitors, ipilimumab, pembrolizumab, and other research topics appear to be at the forefront of this field's research and have the potential to remain a hot research topic in the future. Conclusion: This is the first bibliometric study in the last 30 years to comprehensively map the knowledge structure and trends in the field of research related to ocular melanoma and immunotherapy. The results comprehensively summarize and identify research frontiers for scholars studying immunotherapy associated with ocular melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma.
- Author
-
Goesmann, Lara, Refaian, Nasrin, Bosch, Jacobus J., and Heindl, Ludwig M.
- Subjects
- *
TUMOR microenvironment , *BRAF genes , *OCULAR tumors , *PROGRAMMED cell death 1 receptors , *LYMPHOCYTE transformation , *IMMUNE checkpoint proteins , *MELANOMA - Abstract
Simple Summary: This is the first study on the tumor microenvironment of uveal melanoma with special regard to the localization within the tumor and the eye. Uveal melanoma is the most common malignant tumor of the eye in adults. Regardless of the treatment of the primary tumor, half of the patients with uveal melanoma die due to metastasis in the long run. The major findings of this study are that blood vessels are mainly located in the middle of the tumor and that immune cells (especially CD68-immunopositive macrophages) are mostly found in the outer section of the tumor. Furthermore, this study found a high representation of lymphocyte activation gene-3 (LAG-3) and Galectin-3 in uveal melanoma. These findings could set a foundation for new therapeutic strategies aimed at improving the survival rate of patients with uveal melanoma. Uveal melanoma (UM) is a highly malignant tumor of the eye. Metastatic spread of UM occurs almost exclusively via blood vessels and is of tremendous interest, as half of the patients with uveal melanoma die of metastasis in the long run. The tumor microenvironment consists of all cellular and non-cellular compounds of a solid tumor, except for the tumor cells. This study aims to provide a more detailed understanding of the tumor microenvironment of UM to build the foundation for new therapeutic targets. Fluorescence immunohistochemistry was performed to examine the localization of various cell types in the tumor microenvironment in UM. Furthermore, the presence of LAG-3 and its ligands Galectine-3 and LSECtin was examined to evaluate the potential efficacy of immune checkpoint inhibitor-based therapies. The main findings are that blood vessels are mainly located in the middle of the tumor, and that immune cells are mostly found in the outer section of the tumor. LAG-3 and Galectine-3 were found to be highly represented, whereas LSECtin barely occurred in UM. Both the predominant location of tumor-associated macrophages in the outer section of the tumor and the high presence of LAG-3 and Galectine-3 in the UM serve as attainable therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Ophthalmic applicator displacement as a method of treating large diffuse uveal melanomas.
- Author
-
Markiewicz, Anna, Skórkiewicz, Konrad, Bogdał, Agata, Medoń, Dominik, Świder, Mirella, Korab-Chrzanowska, Elżbieta, Kowal, Joanna, Dębicka-Kumela, Magdalena, and Romanowska-Dixon, Bożena
- Subjects
- *
UVEA cancer , *ENUCLEATION of the eye , *MELANOMA , *TUMOR treatment , *AMERICAN mink , *RADIOISOTOPE brachytherapy - Abstract
Purpose: The presentation of results of an ophthalmic plaque displacement as a brachytherapy treatment method of large diffuse uveal melanomas. Material and methods: This was a retrospective analysis of treatment results of 9 patients with large diffuse uveal melanomas using ophthalmic plaque displacement. Patients were treated with this method in our center between 2012 and 2021 (last follow-up visit in 2023). To achieve appropriate radiation dose distribution for large tumors with a base greater than 18 mm, brachytherapy (106Ru in 7 patients and 125I in 2 patients) with applicator displacement was used as primary treatment. Median follow-up was 2.9 years, and for patients with positive primary treatment results, it was 1.7 months. Median time to local relapse was 2.3 years. Results: In 5 patients, a positive result of local treatment was obtained, out of whom, one patient underwent enucleation due to complications. In the next 4 cases, local recurrence developed. In all tumors, the use of applicator displacement method caused that planning target volume (PTV) was effectively covered with treatment isodose. Conclusions: Brachytherapy with ocular applicator displacement allows for the treatment of tumors with base measurements larger than 18 mm. The application of this method may be considered as an alternative for eye enucleation in particular cases of large diffuse tumors, such as a neoplasm of the eye with vison, or when a patient does not consent to enucleation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Oral isotretinoin and topical retinoid use in a series of young patients with ocular melanoma.
- Author
-
Mishra, Kavita K, Scholey, Jessica E, Daftari, Inder K, Afshar, Armin, Tsai, Tony, Park, Susanna, Quivey, Jeanne M, and Char, Devron H
- Subjects
Isotretinoin ,Ocular melanoma ,Retinoid therapy ,Tretinoin ,Uveal melanoma ,Rare Diseases ,Clinical Research ,Cancer ,Prevention ,Eye Disease and Disorders of Vision - Abstract
PurposeTo describe the first series of six young uveal melanoma (UM) patients with oral isotretinoin and/or topical retinoid therapy prior to diagnosis.ObservationsThe case series is based on clinical observations at our UM quaternary referral center. Six UM patient cases are reported, ages 16-44 years old. All had been using either oral (isotretinoin) and/or topical (tretinoin or tazarotene) retinoid treatment (3 months-~10 years) prior to or at the time of diagnosis (3 of 6 cases). All patients had ocular complaints on presentation, and the onset of certain symptoms corresponded with the course of retinoids. Other potential risk factors or relevant history included Caucasian background, cone-rod dystrophy and active smoker status (Case 2), family history of UM and pregnancy at time of diagnosis (Case 3), past smoking and possible secondary Chernobyl exposure as a baby (Case 5). All patients were treated with proton beam radiotherapy and currently have no sign of recurrent or metastatic disease.Conclusions and importanceRetinoid therapy has been linked to various benign and/or reversible effects on the anterior and posterior eye, though pathophysiology remains not well understood. Uveal melanoma (UM) is a rare cancer diagnosis in young adults. We report here the first case series of young UM patients with a history of retinoid use and ocular complaints. No causal link is claimed and further systematic epidemiologic and biologic study of retinoid therapy and ocular impact may provide additional relevant data, particularly in young ocular melanoma patients.
- Published
- 2020
34. Diagnosis of Choroidal Melanoma
- Author
-
Aronow, Mary E., Gragoudas, Evangelos S., O’Brien, Joan Marie, Section editor, Gombos, Dan, Section editor, Albert, Daniel M., editor, Miller, Joan W., editor, Azar, Dimitri T., editor, and Young, Lucy H., editor
- Published
- 2022
- Full Text
- View/download PDF
35. Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital
- Author
-
Selin Kestel, Feriha Pınar Uyar Göçün, Betül Öğüt, and Özlem Erdem
- Subjects
uveal melanoma ,conjunctival melanoma ,ocular melanoma ,overall survival ,histopathology ,Pathology ,RB1-214 - Abstract
Background We aimed to determine the effect of clinicopathologic features on overall survival among Caucasian ocular melanoma patients in the Central Anatolia region of Turkey. Methods This single-center study included conjunctival (n = 12) and uveal (n = 19) melanoma patients diagnosed between January 2008 and March 2020. Clinicopathologic features and outcomes were reviewed retrospectively. Five cases were tested for BRAF V600 mutations with real-time polymerase chain reaction, and one case was tested with next-generation sequencing. Survival was calculated using the Kaplan-Meier method. Results Thirty-one patients had a mean initial age of 58.32 years (median, 61 years; range 25 to 78 years). There were 13 male and 18 female patients. The median follow-up time was 43.5 months (range, 6 to 155 months) for conjunctival melanoma and 35 months (range, 8 to 151 months) for uveal melanoma. When this study ended, eight of the 12 conjunctival melanoma patients (66.7%) and nine of the 19 uveal melanoma patients (47.4%) had died. The presence of tumor-infiltrating lymphocytes was related to improved overall survival in conjunctival melanoma (p = .014), whereas the presence of ulceration (p = .030), lymphovascular invasion (p = .051), tumor in the left eye (p = .012), tumor thickness of > 2 mm (p = .012), and mitotic count of >1/mm2 (p = .012) reduced the overall survival in conjunctival melanoma. Uveal melanoma tumors with the largest diameter of 9.1–15 mm led to the lowest overall survival among subgroups (p = .035). Involvement of the conjunctiva (p=.005) and lens (p = .003) diminished overall survival in uveal melanoma. BRAF V600 mutation was present in one case of conjunctival melanoma, GNAQ R183Q mutation was present in one case of uveal melanoma. Patients with uveal melanoma presented with an advanced pathological tumor stage compared to those with conjunctival melanoma (p = .019). Conclusions This study confirmed the presence of tumor-infiltrating lymphocytes as a favorable factor in conjunctival melanoma and conjunctival and lens involvement as unfavorable prognostic factors in uveal melanoma for overall survival, respectively.
- Published
- 2022
- Full Text
- View/download PDF
36. A miRNA-based gene therapy nanodrug synergistically enhances pro-inflammatory antitumor immunity against melanoma.
- Author
-
Ma, Yawen, Lin, Huimin, Wang, Peng, Yang, Haocheng, Yu, Jie, Tian, Hao, Li, Tianyu, Ge, Shengfang, Wang, Yilong, Jia, Renbing, Leong, Kam W., and Ruan, Jing
- Subjects
GENE therapy ,MICROPHTHALMIA-associated transcription factor ,IRON oxides ,CATIONIC polymers ,TUMOR suppressor genes ,MELANOMA ,GENETIC vectors - Abstract
MicroRNA (miRNA)-based gene therapy is a robust approach to treating human cancers. However, the low target specificity and safety issues associated with viral vectors have limited the clinical use of miRNA therapeutics. In the present study, we aimed to develop a biocompatible nanocarrier to deliver the tumor suppressor miR-30a-5p for gene therapy of ocular melanoma. The quasi-mesoporous magnetic nanospheres (MMNs) were prepared by polyelectrolytes-mediated self-assembling Fe 3 O 4 nanocrystals; the cationic polymer capped quasi-mesoporous inner tunnels of the MMNs facilitate high miRNA loading and protect from nuclease degradation. Then, the outer layer of the MMNs was modified with a disulfide bond bridged very low molecular weight polyethyleneimine (PEI) network to form redox-responsive nanospheres (rMMNs) that enhance the miRNA payload and enable miRNA release under glutathione-dominant tumor microenvironment. The miR-30a-5p loaded rMMNs nanodrug (miR-30a-5p@rMMNs) upregulated miR-30a-5p level and inhibited malignant phenotypes of ocular melanoma by targeting the transcription factor E2F7 both in vitro and in vivo. Additionally, rMMNs act as an enhancer to increase cancer cell apoptosis by modulating M1-like macrophage polarization and activating Fenton reaction. Thus, the rMMNs is a promising miRNA carrier for gene therapy and could enhance pro-inflammatory immunity in melanoma and other cancers. • miR-30a-5p@rMMNs inhibited malignant phenotypes of ocular melanoma both in vitro and in vivo. • The rMMNs promoted M1 macrophage polarization thus synergistically enhancing pro-inflammatory anti-tumor immunity against melanoma. • The rMMNs showed no obvious toxicity under the injection dose. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Oncoviruses and melanomas: A retrospective study and literature review.
- Author
-
Ciccarese, Giulia, Drago, Francesco, Broccolo, Francesco, Pastorino, Angela, Pizzatti, Laura, Atzori, Laura, Pilloni, Luca, Santinelli, Davide, Urbani, Alice, Parodi, Aurora, Tomasini, Carlo, and Rongioletti, Franco
- Subjects
MELANOMA ,RETROVIRUSES ,LITERATURE reviews ,POLYMERASE chain reaction - Abstract
The role of human oncoviruses in melanoma has been poorly investigated. The aim of this study was to investigate the association between oncoviruses and melanomas searching for human papillomavirus (HPV), Epstein Barr virus (EBV), and human herpesvirus 8DNA in melanoma specimens. Formalin‐fixed and paraffin‐embedded tissue specimens of cutaneous, mucosal, and ocular melanomas (OM) were selected from the Pathology Departments of the Galliera Hospital (Genoa) and the University Hospitals of Turin and Cagliari. Cutaneous and mucosal nevi have been collected as controls. The oncoviruses search has been performed with different polymerase chain reaction reagent kits. Fifty‐four melanomas (25 mucosal, 12 ocular, and 17 cutaneous) and 26 nevi (15 cutaneous and 11 mucosal) specimens were selected. The detection rate for one of the investigated oncoviruses was 17% in mucosal, 20% in ocular, and 0% in cutaneous melanomas (CMs). Despite the differences between groups seeming remarkable, there was no statistical significance (p > 0.5). Our data do not support a primary role of oncoviruses in melanoma carcinogenesis; however, the finding of HPV and EBV DNA in a considerable fraction of mucosal and OMs suggests that these viruses may act as cofactors in the development of extra‐CMs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.
- Author
-
Waninger, Jessica J., Fecher, Leslie A., Lao, Christopher, Yentz, Sarah, Green, Michael D., and Demirci, Hakan
- Subjects
- *
MELANOMA prognosis , *IMMUNE checkpoint inhibitors , *MELANOMA , *UVEA cancer , *MONOCLONAL antibodies , *CANCER patients , *TREATMENT effectiveness , *NEUTROPHIL lymphocyte ratio , *DESCRIPTIVE statistics , *TUMOR markers , *PROGRESSION-free survival , *EVALUATION - Abstract
Simple Summary: Uveal melanoma is a rare form of melanoma but is the most common tumor in the eye. Despite having effective treatments for the initial tumor, many patients experience the spread of their cancer to distant body sites. There is no uniform way of treating metastatic disease, but physicians often use therapies that harness the patient's immune system because these same treatments have been very effective in other types of melanoma. Not all patients respond to this therapy though, and some develop toxicity related to the treatment. The goal of this paper was to identify features or blood markers that may help determine response to treatment early. Specifically, we analyzed a molecule called lactate dehydrogenase (LDH) and the ratio of different white blood cells at the start of therapy and 2 months after treatment was started. We found that these non-invasive blood markers could be useful in determining which patients are responding to treatment. Background: There is no standardized treatment for metastatic uveal melanoma (MUM) but immune checkpoint inhibitors (ICI) are increasingly used. While ICI has transformed the survival of metastatic cutaneous melanoma, MUM patients do not equally benefit. Factors known to affect ICI response include the hematologic markers, lactate dehydrogenase (LDH) and neutrophil:lymphocyte ratio (NLR). We evaluated the prognostic value of LDH and NLR at the start of ICI and on treatment in MUM. Methods: MUM patients were treated between August 2006 and May 2022 with combination ipilimumab/nivolumab or ipilimumab/nivolumab/pembrolizumab single-agent therapy. Univariable (UVA) and multivariable (MVA) analyses were used to assess the prognostic value of predefined baseline factors on progression-free (PFS) and overall survival (OS). Results: In forty-six patients with MUM treated with ICI, elevated baseline and on-treatment LDH was prognostic for OS (start of ICI, HR (95% CI): 3.6 (1.9–7.0), p < 0.01; on-treatment, HR (95% CI): 3.7 (1.6–8.8), p < 0.01) and PFS (start of ICI, (HR (95% CI): 2.8 (1.5–5.4), p < 0.0001); on-treatment LDH (HR (95% CI): 2.2 (1.1–4.3), p < 0.01). On-treatment NLR was prognostic for PFS (HR (95% CI): 1.9 (1.0–3.9), p < 0.01). On-treatment LDH remained an important contributor to survival on MVA (OS: HR (95% CI): 1.001 (1.00–1.002), p < 0.05); PFS: HR (95% CI): 1.001 (1.00–1.002), p < 0.01). Conclusions: This study demonstrates that LDH and NLR could be useful in the prognostication of MUM patients treated with ICI. Additional studies are needed to confirm the importance of these and other prognostic biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
39. Methylation-driven gene DLL3 is a potential prognostic biomarker in ocular melanoma correlating with metastasis.
- Author
-
Ludi Yang, Gaoming Wang, Hanhan Shi, Shichong Jia, Jing Ruan, Ran Cui, and Shengfang Ge
- Subjects
PROGRESSION-free survival ,GENE expression profiling ,BRAF genes ,PROGNOSIS ,MELANOMA ,BIOMARKERS ,DNA methylation - Abstract
Background: Ocular melanoma is an aggressive malignancy with a high rate of metastasis and poor prognosis. Increasing evidence indicated that DNA methylation plays an important role in the occurrence and development of ocular melanoma. Hence, exploring new diagnostic and prognostic biomarkers at the genetic level may be beneficial to the prognosis of patients with ocular melanoma. Methods: We collected DNA methylation and gene expression profiles of human UM (uveal melanoma) and CM (conjunctival melanoma) samples from various datasets. We conducted differential methylation and expression analyses to screen the potential biomarkers. Correlation analysis was performed to investigate the relationships between the expression level of DLL3 (delta-like protein 3) and the methylation level of its corresponding CpGs. We explored the prognostic and diagnostic value of DLL3 in UM and CM. Functional annotation and GSEA (gene set enrichment analysis) were applied to get insight into the possible biological roles of DLL3. A cohort of 60 ocular melanoma patients as well as UM and CM cell lines were used to validate our findings in bioinformatic analyses. Results: We found that DLL3 was a methylation-driven gene correlating with UM metastasis. The CpGs of DLL3 are mainly located in the gene body and their methylation level positively correlated to DLL3 expression. Multivariate Cox regression analysis revealed that DLL3 was an independent protective factor for UM patients. High DLL3 expression significantly prolonged the overall survival and disease-free survival of UM patients. DLL3 also showed a promising power to distinguish CM from normal tissues. Functional annotation exhibited that DLL3 may suppress UM progression through modulating immune activities and down-regulating various signaling pathways. External datasets, biospecimens, and cell lines further validated the aberrant expression and prognostic role of DLL3 in ocular melanoma. Conclusion: Methylation-driven gene DLL3 could serve as a new potential diagnostic and prognostic biomarker in ocular melanoma. Our findings may contribute to improving the clinical outcomes of patients with UM or CM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
40. RBMS1 reflects a distinct microenvironment and promotes tumor progression in ocular melanoma.
- Author
-
Yang, Ludi, Wang, Gaoming, Tian, Hao, Jia, Shichong, Wang, Shaoyun, Cui, Ran, and Zhuang, Ai
- Subjects
- *
GENE expression , *TUMOR microenvironment , *MACHINE learning , *DNA methylation , *CANCER invasiveness - Abstract
Ocular melanoma, including uveal melanoma (UM) and conjunctival melanoma (CM), is the most common ocular cancer among adults with a high rate of recurrence and poor prognosis. Loss of epigenetic homeostasis disturbed gene expression patterns, resulting in oncogenesis. Herein, we comprehensively analyzed the DNA methylation, transcriptome profiles, and corresponding clinical information of UM patients through multiple machine-learning algorithms, finding that a methylation-driven gene RBMS1 was correlated with poor clinical outcomes of UM patients. RNA-seq and single-cell RNA-seq analyses revealed that RBMS1 reflected diverse tumor microenvironments, where high RBMS1 expression marked an immune active TME. Furthermore, we found that tumor cells were identified to have the higher communication probability in RBMS1+ state. The functional enrichment analysis revealed that RBMS1 was associated with pigment granule and melanosome, participating in cell proliferation as well as apoptotic signaling pathway. Biological experiments were performed and demonstrated that the silencing of RBMS1 inhibited ocular melanoma proliferation and promoted apoptosis. Our study highlighted that RBMS1 reflects a distinct microenvironment and promotes tumor progression in ocular melanoma, contributing to the therapeutic customization and clinical decision-making. • We first demonstrated that a methylation-driven gene named RBMS1 was correlated with poor clinical outcomes. • We validated the expression level and the biological function of RBMS1 in ocular melanoma samples. • We provided evidence for the determination of an individualized therapeutic treatment for ocular melanoma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Nanoparticles for the Treatment of Uveal Melanoma
- Author
-
Narvekar, Abhijit, Rich, Cadmus, Savinainen, Anneli, Kim, Ivana K., and Bernicker, Eric H., editor
- Published
- 2021
- Full Text
- View/download PDF
42. Diagnostic and therapeutic management of patients with ocular melanomas – recommendations of the Polish Society of Oncology.
- Author
-
Rutkowski, Piotr, Romanowska-Dixon, Bożena, Markiewicz, Anna, Zieniewicz, Krzysztof, Kozak, Katarzyna, Rogala, Paweł, Świtaj, Tomasz, and Dudzisz-Śledź, Monika
- Subjects
- *
UVEA cancer , *MELANOMA , *MUCOUS membranes , *ONCOLOGY , *DISEASE management , *THERAPEUTICS - Abstract
Uveal melanoma is the most common malignant neoplasm of the eyeball, developing from melanocytes of the uveal membrane of the eye, which is significantly different from melanoma of the conjunctiva, mucous membranes and skin. The management of this disease is therefore different from that of other forms of melanoma. The disease is most often confined to the eye and its local treatment includes radiation therapy and surgery. Some patients, despite successful local treatment, develop distant metastases, most often located in the liver. The guidelines presented here cover the principles of diagnosis, prognostic evaluation and treatment of both the disease confined to the eyeball and the disease at the metastatic stage. The principles of management of conjunctival melanoma are also discussed. The recommen)dations are based on a review of the literature and expert opinion, and are accompanied by an assessment of their strength and reliability [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
43. Ocular malignancies treated with iodine-125 low dose rate (LDR) brachytherapy at a single high-volume institution: A retrospective review.
- Author
-
Richards, Zachary, Nguyen, My-Lien, Kutteh, Michael, Ahmad, Salahuddin, Henson, Christina, Firestone, Brian, Herman, Terence S., and Herman, Tania De La Fuente
- Subjects
- *
LOW dose rate brachytherapy , *RADIOISOTOPE brachytherapy , *RETINAL detachment , *CHOROID , *OPTIC disc , *RETROSPECTIVE studies , *VITREOUS body , *INTRAOCULAR lenses - Abstract
The aim of our study is to document our cases of choroidal melanoma treated with low dose rate (LDR) brachytherapy and to correlate the dosimetry and radiobiology with clinical effects and oncologic outcomes. Data from 157 patients treated from 2014 to 2018 with LDR brachytherapy were used for this investigation. Treatments used a collaborative ocular melanoma study eye plaque and Iodine-125 radioactive seeds. The seeds activities were chosen to deliver 85 Gy to the tumor apex or to a prescription point (if the apex < 5 mm). The plaque sizes used were 10, 12, 14, 16, 18, 20, and 22 mm including notched or deep notched. The plaques were modeled in Varian BrachyVision version 11.6 (Varian Medical Systems) with seed coordinates from the AAPM Task Group 129. The Task Group 43 from AAPM was used for brachytherapy dose planning. Dose data were extracted for the apex, prescription point, sclera, retina opposite to the implant, lens, macula, and optic disc. The radiobiological dosimetry were calculated using appropriate α/β ratios found in the literature and then correlated to clinical side effects. Average biologically effective dose for associated organs at risk were calculated in cases where toxicity occurred. These included: radiation cataract (70.66 Gy), disc atrophy (475.49 Gy), foveal atrophy (263.07 Gy), radiation papillopathy (373.45 Gy), radiation maculopathy (213.62 Gy), vitreous hemorrhage (1437.68 Gy), vascular occlusion (1080.93 Gy), nonproliferative retinopathy (1066.89 Gy), proliferative retinopathy (1590.71 Gy), exudative retinal detachment (1364.32 Gy), and rhegmatogenous retinal detachment (2265.54 Gy). Average biologically effective dose was higher in patients who developed radiation induced long term side effects than in the whole patient population except for radiation maculopathy. In spite of the small patient population and short-term follow-up, it is of interest to correlate the radiation induced effects and create a guideline for the improvement of the treatment of patients treated with LDR brachytherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
- Published
- 2019
45. The Role of Inflammation in Ocular Tumours
- Published
- 2019
46. Genetic Analysis of Melanoma Types Using Japanese Genomic Database.
- Author
-
Matsumoto H, Nagano H, Kyutoku T, and Yamashita M
- Abstract
Objectives: The purpose of this study is to compare genetic mutations, tumor mutation burden (TMB), and the effects of molecular targeted drugs and immune checkpoint inhibitors (ICIs) in head and neck mucosal melanoma (HNMUM) with those in skin melanoma (SKM) and ocular melanoma (OM)., Methods: Data were analyzed for 72 consecutive patients with HNMUM, including 366 with SKM and 31 with OM, registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C-CAT) between June 2019 and October 2023. Genetic alterations and TMB were determined by FoundationOne CDx next-generation sequencing., Results: The top 10 mutations in HNMUM were RAD21 (47.2%), NBN (45.8%), MYC (40.3%), LYN (31.9%), NRAS (29.1%), IRF4 (23.6%), DAXX (22.2%), KIT (22.2%), NOTCH3 (20.8%), and DDR1 (19.4%), with 16.6 ± 0.8 (mean ± SEM) mutations/individual. In SKM, BRAF (p = 0.04) mutation was associated with a significantly better prognosis. The TMB values were 5.7 ± 2.1 (mean ± SEM) in HNMUM, 4.1 ± 0.2 in SKM, and 3.4 ± 0.9 in OM, with no significant differences among the three groups. The median survival time for patients with distant metastases was 803 (95% confidence interval: 539-NA) days for HNMUM, 1413 (831-2172) days for SKM, and 1138 (438-NA) days for OM., Conclusions: The top 10 mutations in HNMUM are closer to those in OM than those in SKM. There was no significant difference in TMB values or survival rates with regard to the therapeutic effect of ICIs among the diseases, which suggests that current treatment of HNMUM with ICIs is appropriate., Level of Evidence: 3 Laryngoscope, 2024., (© 2024 The Author(s). The Laryngoscope published by Wiley Periodicals LLC on behalf of The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
47. A Novel Melanin-Targeted 18 F-PFPN Positron Emission Tomography Imaging for Diagnosing Ocular and Orbital Melanoma.
- Author
-
Wang Y, Wang X, Zhang J, Zhang X, Cheng Y, and Jiang F
- Subjects
- Humans, Male, Middle Aged, Female, Adult, Retrospective Studies, Feasibility Studies, Picolinic Acids, Melanoma diagnostic imaging, Melanoma metabolism, Melanins metabolism, Radiopharmaceuticals, Positron-Emission Tomography methods, Orbital Neoplasms diagnostic imaging, Orbital Neoplasms metabolism, Fluorodeoxyglucose F18, Eye Neoplasms diagnostic imaging, Eye Neoplasms metabolism
- Abstract
Objective:
18 F-N-(2-(Diethylamino)ethyl)-5-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy) picolinamide (18 F-PFPN) is a novel positron emission tomography (PET) probe designed to specifically targets melanin. This study aimed to evaluate the diagnostic feasibility of18 F-PFPN in patients with ocular or orbital melanoma., Materials and Methods: Three patients with pathologically confirmed ocular or orbital melanoma (one male, two females; age 41-59 years) were retrospectively reviewed. Each patient underwent comprehensive18 F-PFPN and18 F-fluorodeoxyglucose (18 F-FDG) PET scans. The maximum standardized uptake value (SUVmax ) of the lesion and the interference caused by background tissue were compared between18 F-PFPN and18 F-FDG PET imaging. In addition, the effect of intrinsic pigments in the uvea and retina on the interpretation of the results was examined. The contralateral non-tumorous eye of each patient served as a control., Results: All primary tumors (3/3) were detected using18 F-PFPN PET, while only two primary tumors were detected using18 F-FDG PET. Within each lesion, the SUVmax of18 F-PFPN was 2.6 to 8.3 times higher than that of18 F-FDG. Regarding the quality of PET imaging, the physiological uptake of18 F-FDG PET in the brain and periocular tissues limited the imaging of tumors. However,18 F-PFPN PET minimized this interference. Notably, intrinsic pigments in the uvea and retina did not cause abnormal concentrations of18 F-PFPN, as no anomalous uptake of18 F-PFPN was detected in the healthy contralateral eyes., Conclusion: Compared to18 F-FDG,18 F-PFPN demonstrated higher detection rates for ocular and orbital melanomas with minimal interference from surrounding tissues. This suggests that18 F-PFPN could be a promising clinical diagnostic tool for distinguishing malignant melanoma from benign pigmentation in ocular and orbital melanomas., Competing Interests: The authors have no potential conflicts of interest to disclose., (Copyright © 2024 The Korean Society of Radiology.)- Published
- 2024
- Full Text
- View/download PDF
48. Ocular Cancer Stem Cells: Advances in Therapeutic Interventions
- Author
-
Upadhyay, Upasna, Sen, Raaghav, Kaliki, Swathi, Jangamreddy, Jaganmohan R., Pathak, Surajit, editor, and Banerjee, Antara, editor
- Published
- 2020
- Full Text
- View/download PDF
49. STA-9090(Ganetespib) in Metastatic Ocular Melanoma
- Author
-
Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Synta Pharmaceuticals Corp., and F. Stephen Hodi, MD, Melanoma Disease Center Director
- Published
- 2018
50. Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018
- Author
-
Valasapalli S and Guddati AK
- Subjects
ocular melanoma ,mortality ,trend ,incidence ,Medicine (General) ,R5-920 - Abstract
Srijan Valasapalli,1 Achuta Kumar Guddati2 1Department of Medicine, Carle Foundation Hospital, Urbana, IL, 61801, USA; 2Division of Hematology/Oncology, Georgia Cancer Center, Augusta University, Augusta, GA, 30909, USACorrespondence: Achuta Kumar GuddatiDivision of Hematology/Oncology, Georgia Cancer Center, Augusta University, Augusta, GA, 30909, USATel +1 312-404-8928Email aguddati@augusta.eduBackground: Ocular and orbit melanoma is a rare subtype of melanoma for which outcomes have not been adequately reported. We have analyzed the incidence-based mortality trends of ocular and orbit melanoma over 15 years in USA. Most ocular melanomas originate from the uvea and, to a lesser extent, from the conjunctiva. Primary orbital melanoma is exceedingly rare.Methods: The Surveillance, Epidemiology, and End Results (SEER) database was queried to find the incidence-based mortality for all patients diagnosed with ocular and orbit melanoma for the years 2000 to 2018. Results were grouped by gender and race (Caucasian/White, African American/Black, American Indian/Alaskan Native, and Asian/Pacific Islanders). A paired t-test was used to determine the statistically significant difference between various subgroups (p < 0.05).Results: Incidence-based mortality has been the highest in Caucasian/White patients from 2000 to 2018, followed by African American/Black and Asian/Pacific Islander patients. American Indian/Alaskan native patients appear to have the least mortality. There was a statistically significant difference (p< 0.05) in mortality between Caucasian/White patients from 2000 to 2018, and African American/Black and Asian/Pacific Islander patients. The sample size for African American/Black and American Indian/Alaskan native patients was too low to discern a meaningful trend in mortality. Overall, it appears that Caucasian males and females have a far higher and worsening incidence-based mortality compared to other races.Conclusion: Ocular melanoma and orbit melanoma are rare entities that are predominantly seen in Caucasian/White patients. This study shows that incidence-based mortality has been worsening for these patients in the past two decades. These entities have a poor prognosis and have not been studied extensively in immunotherapy trials. There is a need for new clinical trials to help improve mortality rates.Keywords: ocular melanoma, mortality, trend, incidence
- Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.